Find the lowest price from 7,500+ FDA-registered pharmacies. Save up to 90%.
⭐ 4.7/5 Customer Rating
🏅 FDA-Registered Pharmacies
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
Blocks histamine H1 receptors directly at target tissues — a second line of action that manages symptoms even when some mediator release occurs.
Semaglutide combined with NAD+ (nicotinamide adenine dinucleotide) pairs GLP-1 receptor agonist therapy with a critical coenzyme in cellular energy production. This combination targets both appetite reduction and cellular metabolic function, addressing the fatigue and energy decline some patients experience during GLP-1 therapy.
Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Semaglutide activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve insulin sensitivity. NAD+ is a coenzyme present in every living cell, essential for mitochondrial energy production (ATP synthesis), DNA repair, and sirtuin activation. Together, they address both caloric intake reduction and the cellular energy demands that increase during metabolic stress and weight loss.
No commercially available product combines semaglutide with NAD+. NAD+ must be delivered parenterally (by injection or IV) because oral NAD+ is rapidly degraded in the GI tract. Compounding allows prescribers to combine both agents in a single subcutaneous injection, providing GLP-1 therapy alongside direct cellular energy support.
Compounded semaglutide with NAD+ combines a GLP-1 receptor agonist with one of the most fundamental molecules in cellular metabolism. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme required for over 500 enzymatic reactions, including mitochondrial electron transport, DNA repair via PARP enzymes, and sirtuin-mediated cellular maintenance.
NAD+ levels naturally decline with age and can be further depleted during metabolic stress, caloric restriction, and chronic disease. Patients on GLP-1 therapy who experience significant appetite suppression may face compounding metabolic demands that deplete cellular NAD+ pools.
This combination is particularly prescribed in longevity-focused and functional medicine practices where optimizing cellular energy alongside weight management is a treatment priority.
Semaglutide — GLP-1 Receptor Activation
Semaglutide binds to GLP-1 receptors on pancreatic beta cells, hypothalamic neurons, and gastric smooth muscle. It stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces hunger through central appetite regulation.
NAD+ — Cellular Energy and Repair
NAD+ serves as an electron carrier in the mitochondrial electron transport chain, directly powering ATP synthesis. It is also the substrate for sirtuins (SIRT1–SIRT7), which regulate cellular stress responses, inflammation, and metabolic adaptation. NAD+ is consumed by PARP enzymes during DNA repair. Declining NAD+ levels are associated with aging, metabolic dysfunction, and reduced cellular resilience.
Prescribed for patients with a documented clinical need for compounded semaglutide who also benefit from cellular energy and metabolic support:
BIND THIS TO: Mechanism Text CMS field (Rich Text). Then delete this paragraph and add a Rich Text element instead.
Anti-aging and longevity protocols, chronic fatigue, neurodegenerative disease support, addiction recovery, post-COVID fatigue
⚠️ Dosing should be determined by your prescriber. The information below is general guidance only.
Typical semaglutide + NAD+ dosing:
Weeks 1–4: Semaglutide 0.25mg + NAD+ 25–50mg weekly
Weeks 5–8: Semaglutide 0.5mg + NAD+ 25–50mg weekly
Weeks 9–12: Semaglutide 1.0mg + NAD+ 50–100mg weekly
Weeks 13+: Semaglutide 1.7–2.4mg + NAD+ 50–100mg weekly
NAD+ dosing varies significantly by prescriber protocol and pharmacy formulation. Dosing is individualized.
Semaglutide follows the standard 4-week titration schedule. NAD+ in subcutaneous doses is generally well tolerated but some patients report transient flushing, warmth, or mild nausea at higher doses. Starting with a lower NAD+ dose and increasing gradually can minimize these effects. NAD+ side effects resolve quickly and are not related to the semaglutide component.
Subcutaneous Injection — The standard form for this combination. Semaglutide and NAD+ are combined in a single vial for weekly injection. This delivers NAD+ directly to tissues, bypassing GI degradation.
From semaglutide:
From NAD+:
Compounded semaglutide + NAD+ is a 503A patient-specific preparation. NAD+ for injection is not individually FDA-approved; it is compounded as a sterile preparation. The FDA has classified certain NAD+ preparations as drug compounds when compounded for injection. Patients should verify pharmacy licensure and sterility testing certifications.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy production, DNA repair, and metabolic regulation. During GLP-1 therapy, reduced caloric intake and metabolic shifts can increase cellular energy demands. NAD+ supplementation supports mitochondrial function and may help reduce fatigue experienced during treatment.
No. Neither the combination nor compounded NAD+ injections are FDA-approved. However, NAD+ is a naturally occurring molecule with extensive biochemical evidence supporting its role in cellular metabolism. The combination is prepared by licensed compounding pharmacies under a valid prescription.
Typical pricing ranges from $249 to $549 per month. NAD+ is a more expensive active ingredient than B12 or L-carnitine, which is reflected in the higher cost. Compounding Finder helps you compare options from multiple licensed pharmacies.
Oral NAD+ is rapidly degraded in the GI tract and does not meaningfully raise cellular NAD+ levels. Injectable delivery bypasses this limitation. NAD+ precursors like NMN and NR have better oral bioavailability but do not achieve the same acute cellular levels as direct NAD+ injection.
Yes. Compounded semaglutide + NAD+ requires a valid prescription from a licensed healthcare provider.
1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
2. Rajman L, et al. Therapeutic Potential of NAD-Boosting Molecules. Cell Metab. 2018;27(3):529-547.
3. Verdin E. NAD+ in Aging, Metabolism, and Neurodegeneration. Science. 2015;350(6265):1208-1213.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
